Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good morning! WowSers! GapAheavens!
Honestly RGBP is going to go like TSN$P DID.
IMO
GLTA!
anyone called the IR people?
tja RGBP$
4 days of heated exchange of shares, news of any filings and were ready for over $.10
I was not able to reach the company IR person to ask if he might clue us in as to when they will drop the new filings.
the phone number on the web site is not a good number.
the time for an update is now.
hold 'em
glta
It's the golden dip before the storm, golden time to buy right now, by end of the day we might be at $.08 again.
Filings will put this over all this and will put us on the way to $.12-.15
imo.
glta.
yes they really believe in the mRNA vaccines.
"the mRNA vaccines have become a promising platform for cancer immunotherapy. The intellectual property which we licensed from Regen encompasses an exciting method of utilizing mRNA to cause changes in the cancer cells which would stimulate the patient's own immune response to battle this deadly disease."
https://www.otcmarkets.com/stock/ONPH/news/Oncology-Pharma-Inc-Addresses-Pancreatic-Cancer-the-Need-for-an-Effective-Therapy-and-the-Potential-of-mRNA-Technology?id=298095
Good morning fellow RGBP shareholders.
Money to be made here today!
GLTA.
Was it tomorrow that the 55k is being completed?
I think that i read it somewhere that it was.
Just thinking we will likely get a new PR if it does happen tomorrow.
GLTA!
Item 2.01. Completion of acquisition or disposition of Assets
On April 12, 2021 a new Nevada corporation was formed to merge and survive the bankrupt Immune Pharmaceuticals Inc (NJ).
The new corporation retains the same name however is registered in the state of Nevada. The company further has updated its address.
The new corporation is not subject to chapter 7 bankruptcy and has no association with any legal issues relating to the previous corporation
I called the company at the number given on the web site.
It was not a good phone number.
DOES anyone have a good contact number?
thanks
look at all these regulating filings...
https://www.regenbiopharmainc.com/regulatory-filings.html
they said they will have them out as soon as possible.
they are coming soon.
maybe later today, maybe tomorrow, but they are coming.
Glta!
Has anyone called the Investment Relations person lately?
I think it's time too.
I also would think that they may want to uplist to the OTCQB or nasdaq soon but theshare price must rise for that to happen.
anyone have the IR contact info?
EMAIL OR PHONE
TiA
Tomorrows bankroll keep accumulating. consolidating, then .$$$!
Yep, Can't get away from all this fun! lol!
It's going to be a great helper in the search for cancer cures.
good stuff here.
gl.
Beasty isn't it? 700 million so far
Woah! such a nice price $.045 I want more!
ADDED again, great price 5 cent bargains, EOD $.075+
HA! Ha! let her plummet, =tomorrow's buying opportunity!
she's a good vehical folks, buy rhe dips, sell the high's
have fun!
until tomorrow.
lpm
yep! and with becoming current, just fantastik!
buying more. can't let these cheepies go.
got my buy order set for .06, or i'll save it for tomorrows dip
OTC news and buying pressure, no stooping folks!
=No brainer
see ya all tomorrow at $.12's
glta!
Watching for PINK Current to pop in and say "hello"! He-he.
Maybe tonight, maybe tomorrow,...but soon!
ADD another engine on this train.
take us to $.20
glta!
That sentiment is worthy of much repeating, and I hope it does, often!
"Yep..
This money no longer ihub control here.
This is purely outside money pouring in.
No way I'm leaving the party too early folks!:)"
glta!
Chooo---Choooo!, chug,chug! toooot- toooot! $0.10 next stop!
lol.
ha!
make that money!
glta!
RE-HASH, $55000.00 incoming 8 days, 1.5 million 8 days, immediate $50k,
10% royality's, and more from BIOPHARMA GIANT Oncology Pharma, Inc.
FILING UNDERWAY. PINK OR BETTER.
On April 7, 2021 Regen Biopharma, Inc. (“Regen”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby Regen granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property ( “License IP”) for the treatment in humans of pancreatic cancer for a term of fifteen years from April 7, 2021.
The License IP consists of antigen specific cancer vaccines in which modified mRNA is administered to produce epitopes able to produce an immune response which augments likelihood of successful induction of immunity. An epitope is the part of an antigen that is recognized by the immune system.
As consideration to Regen for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to Regen a nonrefundable fee of $55,000 no later than April 20,2021
(b) pay to Regen royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to Regen ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which Regen receives payment
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the text of the Agreement , which is attached to this Current Report on Form 8-K as Exhibit 10.1 and incorporated in this Item 1.01 by reference.
On April 7, 2021 KCL Therapeutics, Inc. (“KCL”) entered into an agreement (“Agreement”) with Oncology Pharma, Inc. (“Licensee”) whereby KCL granted to Licensee an exclusive right and license for the development and commercialization of certain intellectual property (“License IP”) for the treatment in humans of colon cancer for a term of fifteen years from April 7, 2021.
As consideration to KCL for the rights and license granted pursuant to the Agreement Licensee shall:
(a) pay to KCL a nonrefundable fee of Fifty Thousand common shares of Oncology Pharma, Inc. no later than April 20,2021
(b) pay to KCL royalties equal to five percent (5%) of the Net Sales as Net Sales are defined in the Agreement of any Licensed Products in a quarter.
(c) pay to KCL ten percent (10%) of all consideration (in the case of in-kind consideration, at fair market value as monetary consideration) received by Licensee from sublicensees, excluding royalties from sublicensees based on Net Sales of any Licensed Products for which KCL receives payment
Licensed Product is defined in the Agreement as (a) any method, procedure, service or process that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions; and (b) any apparatus, material, equipment, machine or other product that incorporates, uses, used, is covered by, infringes or would infringe any of the License IP in the U.S. or foreign jurisdictions but for the rights granted pursuant to the Agreement.
In the event that development of the License IP by the Licensee is not commenced as of the date that is nine months from the effective date of the Agreement the rights and license granted pursuant to the Agreement shall become nonexclusive.
KCL Therapeutics, Inc. is a wholly owned subsidiary of Regen Biopharma, Inc
1.4 billion shares traded so far today.
End of day run-up still to come..
g.l. investors!
MUCHLY AGREE! HIGHER and HIGHER it is!
glcj
VERY SOON TOO IMO GARYST, VERY SOON.
GL!
Overbought is good too!
https://stockcharts.com/articles/mindfulinvestor/2019/02/bad-overbought-or-good-overbought.html
keep up the presure folks RSI is based on the last 14 days, it's not a real factor again until it bases again, probably next week sometime, also depends upon pink status news, ect.
KEEP UP THE BUYING PRESSURES!
RIPPING TO THE MOON! $0.10 +++ TODAY! BLUE SKY FEVER!
GLTA!
WEEEEE, YIPPPPPIIIIIEEEE!
why sure they are,the cancer biologic s fields help each other.
big investments coming in all week.
this is a Tesoro E. like run, dollars by end of summer, Imo.
Glta!
PINK by end of week. imo.
gl.
PINK NEWS COMING SOON! THEN Institutional investors Weeeee!
Regen Biopharma, Inc. (the “Company”) is in the process of preparing financial statements in order that Company may have such statements audited (in the case of Annual Financial Statements) and reviewed (in the case of Quarterly Financial Statements).
Upon completion of the aforementioned audits and reviews and preparation of the required reports, the Company intends file the following delinquent periodic reports with United States Securities and Exchange Commission:
• Form 10-K for the Fiscal Year ended September 30, 2019
• Form 10-Q for the Quarter ended December 31, 2019
• Form 10-Q for the Quarter ended March 31, 2020
• Form 10-Q for the Quarter ended June 30, 2020
• Form 10-K for the Fiscal Year ended September 30, 2020
• Form 10-Q for the Quarter ended December 31, 2020
GL.
Just the Itty-bitty begining of a $TSN*P like run too!
holding this one for $$$
Pink current soon!
gl.
Nickel time!
Dime
quarter
50 cents
$
glty
Etruscus Outlines Prospective "Red Line" in Large Mineralized "Lightning Strike" Corridor at Rock & Roll
https://stockhouse.com/news/press-releases/2021/04/06/etruscus-outlines-prospective-red-line-in-large-mineralized-lightning-strike#NFB20210411
Confirmation of northern extension to high-grade lithium mineralisation
MAY 23, 2021..
https://backend.otcmarkets.com/otcapi/company/dns/news/document/48468/content
HWKMF BATTERY GRADE 99.8% LITHIUM CARBONATE PRODUCED.
https://www.otcmarkets.com/stock/HWKMF/disclosure
https://sec.report/otc/financial-report/277776
VIDEO:
https://hawkstonemining.com.au/#test-popup-2
https://twitter.com/search?q=HWKMF&src=typeahead_click
HWKMF BATTERY GRADE 99.8% LITHIUM CARBONATE PRODUCED.
https://www.otcmarkets.com/stock/HWKMF/disclosure
https://sec.report/otc/financial-report/277776
VIDEO:
https://hawkstonemining.com.au/#test-popup-2
https://twitter.com/search?q=HWKMF&src=typeahead_click
AGDXF Antioquia Gold- 6,923 troy oz's. X $1,744.20 =$12,075,096.60
Antioquia Gold" or the "Corporation") is pleased to provide a summary of the first quarter 2021 production results for its Cisneros mining operation, and to announce the progress of other ongoing projects
https://news.yahoo.com/antioquia-gold-cisneros-operations-160600748.html
https://www.kitco.com/news/2021-04-08/Antioquia-Gold-ramps-up-production-in-Colombia.html